| Schedule | Constraint | Source |
|---|---|---|
| 42–54 Gy / 3 fx Liver metastases | D21 cc <33.8 Gy, D24 cc <32 Gy | LARK (TROG 17.03) |
| 27.5–60 Gy / 5 fx HCC or metastases | Mean <19 Gy | LARK (TROG 17.03) |
| D21 cc <40 Gy, D24 cc <37.7 Gy | LARK (TROG 17.03) |
A 1.5 cm expansion of the portal vein.
Quoted from eviQ 4026, checked 2026-09-29. Full table with references →
The main bile ducts and portal vein branches at the center of the liver, around the porta hepatis where the portal vein, hepatic artery and bile duct enter.
The central hepatobiliary tract is the region at the hilum of the liver where the main bile ducts leave the liver alongside the portal vein.
In liver SBRT the large central bile ducts behave more like a serial structure than the surrounding liver. High dose here is linked to strictures, cholangitis and hepatobiliary toxicity, so centrally located tumors are limited by this structure rather than by the liver as a whole.
It is built rather than drawn. Toesca 2017 defined it as uniform expansions of the portal vein, testing 5, 10, 15, 20 and 25 mm, and found the 15 mm expansion a suitable surrogate. Check the definition your protocol uses.
Analysis of hepatobiliary toxicity after liver SBRT, using a central hepatobiliary tract structure defined as a 15 mm expansion of the portal vein. Citation checked against Europe PMC; DoseLab has not read the paper.